

AGENDA

[Speakers will be asked to use the Q&A time to set up slide transitions. For sessions without Q&A, 5-minute breaks have been allocated to accommodate these transitions].

Time	Description	Presenting team
Opening session		
09:30-09:45	Welcome and agenda Summary of aims and ongoing studies	Josep M Llovet
09:45-09:55	Welcome by THRIVE Program Officer	Marianne da Silva
Aim 1. To understand the causative processes and key determinants of liver cancer development in adult patients with NAFLD (with/without cirrhosis) and in children		
10:00-10:20	Evaluation of clinical/molecular features to identify determinants of liver cancer onset and progression (WP2)	Helen Reeves & Quentin Anstee – UNEW Team (15 min) Josep M Llovet – Roser Pinyol - IDIBAPS Team (5 min)
10:20-10:30	<i>Q&A</i>	
Aim 2. To decipher the molecular and cellular tumour–host interactions of childhood and adult liver cancer.		
Sub-aim 2a. To create a high-resolution integrative atlas of the tumour microenvironment at the single cell level and using spatial transcriptomics to understand the immune and stroma cell population interactions with the tumour		
10:30-11:00	Single cell / spatial transcriptomic profiling and genomic characterization of liver cancer (WP3)	Jessica Zucman-Rossi – UPCITE Team (15 min)
		Manel Esteller – IJC-CERCA Team (15 min) Josep M Llovet – Roser Pinyol - IDIBAPS Team
11:00-11:10	<i>Q&A</i>	
Sub-aim 2b. This session has been moved to 12:00		

11:10-11:20 Break

Aim 3. To develop reliable tools predicting response to immune therapies in HCC and chemoresistance in HB.		
Sub-aim 3a. To develop biomarkers predicting response/resistance to immune-based regimens in HCC and chemoresistance in HB.		
11:20-11:50	Tumour-host interactions in treated patients and identification of biomarkers (WP5)	Josep M Llovet – IDIBAPS Team (15 min)
		Carolina Armengol - IGTP-CERCA Team (15 min)
11:50-12:00	<i>Q&A</i>	

Aim 2. To decipher the molecular and cellular tumour–host interactions of childhood and adult liver cancer.		
Sub-aim 2b. To explore the intra-tumoral microbiome component of liver cancer, integrating it with spatial maps of the host tumour microenvironment		
12:00-12:30	Characterization of the intratumoral microbiome landscape in liver cancer patients (WP4)	Georg Zeller – LUMC Team (15 min)
		Eran Elinav – WEIZMANN Team (15 min)
12:30-12:40	<i>Q&A</i>	
Aim 3. To develop reliable tools predicting response to immune therapies in HCC and chemoresistance in HB.		
Sub-aim 3b. To generate an algorithm based on artificial intelligence useful for guidance in decision making in the context of liver cancer management		
12:40-12:55	Development of an artificial intelligence-based tool predicting treatment outcome using high-resolution histopathological images (WP6)	Manfred Claassen – EKUT Team (15 min)
12:55-13:00	<i>Q&A</i>	

13:00-14:00 Lunch break

Aim 4. To propose innovative, socially acceptable, and affordable treatments and care solutions, based on the evaluations of their efficacy and toxicity in HCC and HB patient-derived organoids (PDOs) and murine models.		
14:00-14:30	Development of a preclinical drug-testing platform and proposal of new therapeutic strategies overcoming therapy resistances (WP7)	Mathias Heikenwalder – EKUT Team (15 min)
		Jens Puschhof – DKFZ Team (15 min)
14:30-14:40	<i>Q&A</i>	
Aim 5. To integrate our discoveries with pre-existing resources, and support the development of the UNCAN.eu platform. THRIVE will foster Open and FAIR Research by sharing the generated knowledge and data among EU researchers to maximize the societal benefit.		
14:40-14:55	Data management and integration in existing research infrastructures (WP8)	Sven Nahnsen – EKUT Team (15 min)
14:55-15:05	<i>Q&A</i>	

15:05-15:10 Break

Aim 6. To establish strategies to make health policy makers and healthcare professionals aware of the THRIVE results.		
15:10-15:20	Project management and coordination (WP9) Dissemination, communication, exploitation and liaison with EU-funded initiatives (WP10)	Paola Cesaroni – INN-ACTA (10 min)
15:20-15:30	<i>Q&A</i>	
15:30-15:50	Ensure social impact and viability within and beyond the grant period (WP11)	EASL representative (5 min)
		Veronika Vsetickova – ELPA (10 min)
15:50-16:00	<i>Q&A</i>	

Understanding (Tumour-host interactions) cluster		
16:00-16:10	Overview of the Understanding (Tumour-host interactions) cluster	Roser Pinyol - FRCB-IDIBAPS & Paola Cesaroni - INN-ACTA (10 min)
External Advisory Board		
16:10-16:40	Comments from the External Advisory Board	EAB representative (30 min)
Meeting closure		
16:40-16:50	Final discussion	Roser Pinyol – FRCB-IDIBAPS
16:50-17:00	Conclusions and closing remarks	Josep M Llovet – FRCB-IDIBAPS

Zoom link:

<https://us06web.zoom.us/j/81942580562?pwd=6bb7jq7keDwrGaJgrDJXorm84d0lqv.1>

ID: 819 4258 0562

Passcode: 436759



Funded by the European Union under Grant Agreement No. 101136622.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.

Organization and Graphic project by:

